Daewoong Pharmaceutical's botulinum toxin drug Nabota broke a new quarterly sales record in North America. Sales also improved in the second quarter following the first quarter, surpassing 90 billion won in sales in the first half.

Daewoong Pharmaceutical's partner Evolus announced on the 3rd (local time) that its sales of Jubo (Nabota) reached $37.16 million in the second quarter. This is an increase of 46.3% compared to the same period last year. This quarter's sales are the highest since Navota's launch in North America in the second quarter of 2019. It surpassed 34.66 million dollars in the fourth quarter of last year, breaking a new quarterly sales record. Nabota's sales in North America in the fir